Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash & Equivalents (2016 - 2025)

China Pharma Holdings' Cash & Equivalents history spans 16 years, with the latest figure at $345112.0 for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 44.95% year-over-year to $345112.0; the TTM value through Dec 2025 reached $345112.0, down 44.95%, while the annual FY2025 figure was $345112.0, 44.95% down from the prior year.
  • Cash & Equivalents reached $345112.0 in Q4 2025 per CPHI's latest filing, up from $300000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.9 million in Q4 2021 to a low of $300000.0 in Q3 2025.
  • Average Cash & Equivalents over 5 years is $1.4 million, with a median of $870395.5 recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 642.96% in 2022, then crashed 68.59% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $4.9 million in 2021, then tumbled by 58.22% to $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plummeted by 55.97% to $626879.0 in 2024, then crashed by 44.95% to $345112.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Cash & Equivalents are $345112.0 (Q4 2025), $300000.0 (Q3 2025), and $625032.0 (Q2 2025).